There’s no denying it: the radiopharmaceuticals boom is here to stay. | Telix on Tuesday unveiled the spin-off of Rhine ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

The upcoming winter months bring with them the annual cold and flu season—as well as “cuffing season” for singles everywhere.

With Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc ...

MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 ...

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one.

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific ...

In addition to Nucleus’ facility at the Mayo Clinic in Rochester, Minnesota, these sites will bring radiopharmaceutical ...

After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...